Dossier
most-favored-nation deals
Coverage of most-favored-nation deals in the Nexus archive.
- Trump slashes Medicare drug subsidies, cutting against affordability message
President Trump's decision to end a Medicare drug subsidy program could increase monthly costs for millions of seniors, conflicting with his stated goal of reducing drug costs through initiatives like TrumpRx and 'most-favored-nation' deals.
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
President Trump's most-favored-nation drug pricing deals with 17 drugmakers will be tested by three new prescription drugs set to launch soon. The drugs, Baxfendy (hypertension), Awiqli (insulin), and Veppanu (cancer), will offer the first public insight into the practical impacts of these secretive pricing agreements.